Abstract
The ability of tumors to develop resistance to cytotoxic therapies has been a major obstacle in the clinical management of cancer. In addition, dose-limiting toxicity represents yet another impediment in the application of traditional therapeutics. To enhance the sensitivity of tumors to radio-therapeutics, researchers are increasingly turning to nitric oxide for its potential as a powerful adjuvant to existing therapies. Here, we review the aptitude of nitric oxide to serve as a radio-sensitizing, adjuvant therapeutic for the clinical management of cancer.
Keywords: Adjuvant therapy, cancer, nitric oxide, oncology, radiotherapy, therapeutic delivery.
Related Journals
Current Drug Safety
Inflammation & Allergy - Drug Targets (Discontinued)
Recent Patents on Anti-Infective Drug Discovery
Current Drug Discovery Technologies
Current Drug Targets - Inflammation & Allergy
Current Bioactive Compounds
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Anti-Cancer Agents in Medicinal Chemistry
Current Drug Targets
Letters in Drug Design & Discovery
Related Books
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Advances in Cancer Drug Targets
Advances in Cancer Drug Targets
Advances in Cancer Drug Targets
Angiogenesis & Therapeutic Targets In Cancer
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development